Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript [Seeking Alpha]